Trade Mark Journal No.2021/053 31 December 2021
WO0000001610144 (5,35,42)
Office of origin: United States of America
Date of International Registration:10 March 2021
Date of designation in the UK:
10 March 2021

International priority date claimed: 2 March 2021
(United States of America)
(90555191)
- Class 5
- Pharmaceutical preparations and substances for use in the treatment of autoimmune disorders, inflammatory diseases and conditions, cancer, and infectious diseases.
- Class 35
- Providing assistance in the field of product commercialization for third parties of pharmaceuticals and substances for the treatment of autoimmune disorders, inflammatory diseases and conditions, metabolic disorders, allergies, cancer, and infectious diseases.
- Class 42
- Discovery, research, and development of pharmaceuticals and substances for the treatment of autoimmune disorders, inflammatory diseases and conditions, metabolic disorders, allergies, cancer, and infectious diseases; discovery, research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and biotechnology.
MacroGenics, Inc.
Representative: Mills & Reeve LLP, Botanic House, 100 Hills Road Cambridge CB2 1PH UNITED KINGDOM